Anebulo Pharmaceuticals Approves Reverse Stock Split to Terminate Nasdaq Listing.

Anebulo Pharmaceuticals' board has approved a plan to terminate its stock registration, recommending a reverse stock split at a ratio of 1-for-2,500 to 1-for-7,500. The company's board and a special committee of independent directors made the decision as part of a going-private transaction.

AUSTIN, Texas – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing solutions for people suffering from acute cannabis-induced toxic effects, has approved a plan to terminate its stock registration through a reverse stock split. The company's board of directors and a special committee of independent directors have recommended a reverse stock split at a ratio of 1-for-2,500 to 1-for-7,500, which is part of a going-private transaction [1].

The reverse stock split aims to reduce the number of the company's stockholders, enabling Anebulo to qualify to terminate its registration as a Securities and Exchange Commission (SEC) reporting company. The exact ratio of the reverse stock split will be set within the specified range and determined by the board without further stockholder approval [1].

As part of the reverse stock split, common stockholders will receive cash in the amount of $3.50 per pre-split share in lieu of any fractional shares of post-split common stock. Holders of fewer than a minimum number of shares, which will be between 2,500 and 7,500 shares depending on the chosen ratio, will not remain Anebulo stockholders after the reverse stock split. Stockholders with more than the minimum number of shares will continue to hold one share of post-split common stock for every minimum number of pre-split shares they own, and will receive cash for any fractional shares resulting from the split [1].

The $3.50 per pre-split share represents a 91% premium over the closing price of the company's common stock on July 22, 2025. Anebulo believes that the cost and expense of being a public reporting company have become too burdensome, given its strategy to develop its product candidates, reduce operating costs, and return maximum value to its stockholders [1].

The reverse stock split is subject to stockholder approval and certain other conditions. The board may abandon the proposed transaction at any time prior to completion if it determines that the transaction is no longer in the best interests of the company or its stockholders [1].

Anebulo is currently developing its lead product candidate, selonabant, which has completed a Phase 2 clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication in healthy adults challenged with oral THC. The company is prioritizing the advancement of a selonabant IV formulation for pediatric patients with acute cannabis-induced toxicity, which it believes offers a faster timeline to approval relative to the adult oral product [1].

Forward-looking statements in this press release are subject to risks and uncertainties, including the potential failure of the proposed reverse stock split to be consummated, SEC regulatory review, and changes in the company's projected cost savings and strategy [1].

References:
[1] Anebulo Pharmaceuticals, Inc. (2025). Anebulo Pharmaceuticals Approves Plan to Terminate Registration with Reverse Stock Split. Retrieved from [https://www.stocktitan.net/news/ANEB/anebulo-pharmaceuticals-approves-plan-to-terminate-registration-of-36nb7d18ef1r.html](https://www.stocktitan.net/news/ANEB/anebulo-pharmaceuticals-approves-plan-to-terminate-registration-of-36nb7d18ef1r.html)